Get the Stockscreener App
284.57
0.83%
-2.38
After Hours:
284.57
Krystal Biotech Inc stock is traded at $284.57, with a volume of 414.55K.
It is down -0.83% in the last 24 hours and up +9.05% over the past month.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
See More
Previous Close:
$286.95
Open:
$291.12
24h Volume:
414.55K
Relative Volume:
1.45
Market Cap:
$8.39B
Revenue:
$389.13M
Net Income/Loss:
$204.83M
P/E Ratio:
41.58
EPS:
6.8443
Net Cash Flow:
$188.91M
1W Performance:
+5.68%
1M Performance:
+9.05%
6M Performance:
+42.37%
1Y Performance:
+75.35%
1-Day Range:
$283.50
$303.00
1-Week Range:
$251.97
$303.00
52-Week Range:
$122.80
$303.00
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
284.57 | 8.46B | 389.13M | 204.83M | 188.91M | 6.8443 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus - sharewise.com
Krystal Biotech Q1 2026 Earnings Call Transcript - Sahm
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results - Benzinga
Krystal Biotech Q1 2026 earnings preview - MSN
Krystal Biotech stock hits all-time high at 301.99 USD - Investing.com
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2026 Earnings Call Transcript - Insider Monkey
A Look At Krystal Biotech (KRYS) Valuation After Recent Share Price Momentum - Yahoo Finance
Krystal Biotech Earnings Call Highlights Profitable Growth - TipRanks
Krystal Biotech Reports Strong Q1 2026 Earnings with VYJUVEK Gro - GuruFocus
Krystal Biotech jumps as Q1 results show strong VYJUVEK growth and upbeat pipeline/regulatory updates - Quiver Quantitative
Krystal Biotech Jumps 5.3% Amid Sector-Wide Rally - AlphaStreet
Why Is Krystal Biotech (KRYS) Jumping 5.2%? - AlphaStreet
Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end - MSN
Krystal Biotech Releases Q1 2026 Financial Results - AlphaStreet
Krystal Biotech, Inc. Reports Strong Q1 2026 Financial Results with $116 Million Revenue and Significant Net Income Growth - Minichart
Krystal (KRYS) Q1 2026 Earnings Transcript - The Globe and Mail
Krystal Biotech, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Krystal Biotech : First Quarter 2026 Earnings Call - marketscreener.com
KRYS: Q1 2026 delivered robust revenue and EPS growth, with expanding global VYJUVEK sales - TradingView
BofA cuts Krystal Biotech stock price target on revenue mix shift By Investing.com - Investing.com Australia
Krystal Biotech Reports Strong Q1 2026 Results: $116.4M VYJUVEK Revenue, Pipeline Advancements, and $1B Cash Reserves - Minichart
Krystal (KRYS) Q1 2025 Earnings Transcript - The Globe and Mail
Krystal Biotech, Inc. (KRYS) tops Q1 earnings and revenue estimates - MSN
BofA cuts Krystal Biotech stock price target on revenue mix shift - Investing.com UK
KRYS: Q1 revenue rose 32% to $116.4M, with robust margins and major clinical milestones ahead - TradingView
Krystal Biotech (KRYS) Projects FY26 R&D and SG&A Expenses of $1 - GuruFocus
Krystal Biotech Q1 Earnings Call Highlights - Yahoo Finance
Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Transcript : Krystal Biotech, Inc., Q1 2026 Earnings Call, May 04, 2026 - marketscreener.com
KRYS: Q1 revenue grew 32% year-over-year to $116.4M, with robust VYJUVEK sales and 95% gross margin - TradingView
Earnings call transcript: Krystal Biotech Q1 2026 beats earnings expectations By Investing.com - Investing.com Canada
Krystal Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Krystal Biotech (KRYS) Reports Strong Q1 Revenue, CEO Highlights Growth Momentum - GuruFocus
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
KRYSTAL BIOTECH ($KRYS) Releases Q1 2026 Earnings - Quiver Quantitative
Krystal Biotech stock rises over 6% on earnings beat and strong revenue By Investing.com - Investing.com South Africa
Krystal Biotech stock rises over 6% on earnings beat and strong revenue - Investing.com
Krystal Biotech reports $116.4M in sales as key eye study fills - Stock Titan
Earnings Flash (KRYS) Krystal Biotech Posts Q1 EPS $1.83, vs. FactSet Est of $1.44 - marketscreener.com
Krystal Biotech (NASDAQ: KRYS) spouses report 11.5% stake - Stock Titan
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q1 Revenue $116.4M, vs. FactSet Est of $112.1M - marketscreener.com
Krystal Biotech (KRYS) grows VYJUVEK sales 32% and advances late-stage gene therapy pipeline - Stock Titan
Strong VYJUVEK sales lift Krystal Biotech (NASDAQ: KRYS) Q1 profit - Stock Titan
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results - marketscreener.com
BRIEF-Krystal Biotech Q1 Net Income USD 55.932 Million - TradingView
What Krystal Biotech (KRYS)'s RMAT Win for KB707 in Lung Cancer Means For Shareholders - Sahm
Krystal Biotech (KRYS) Valuation Check After Strong One Year Shareholder Returns - Sahm
Trading the Move, Not the Narrative: (KRYS) Edition - Stock Traders Daily
How The Krystal Biotech (KRYS) Narrative Is Shifting With Vyjuvek And Late Stage Pipeline - Yahoo Finance
Krystal Biotech (KRYS) Q1 2026 Preview: EPS Est. $1.42, Reports May 4 - AlphaStreet
All eyes on Krystal Biotech earnings amid pipeline expansion - Investing.com UK
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):